MASH Unraveled: Molecular Drivers of Steatohepatitis and Cancer Risk in MASLD
TL;DR Summary
This Nature review outlines how MASLD progresses to MASH through insulin resistance, lipid dysregulation and lipotoxicity, genetic risk variants (e.g., PNPLA3, TM6SF2, HSD17B13), adipose–immune dysfunction, fibrogenesis and gut–liver axis disturbances; it highlights progression to fibrosis, cirrhosis and hepatocellular carcinoma, and notes advances in polygenic risk scores and targeted therapies addressing lipogenesis, mitochondrial metabolism and bile acid signaling, underscoring MASLD/MASH as a multi‑organ disease with translational therapeutic potential.
- Molecular mechanisms and pathogenesis of MASH Nature
- Scientists now identify five distinct subtypes of common fatty liver disease Labmate Online
- Mayo Clinic researchers publish key studies on IBS, liver disease, AI ultrasound tool Post Bulletin
- 5 subtypes of common liver disease discovered - including rapidly progressing genetic forms Mayo Clinic News Network
- Liver Disease May Not Be One Disease At All, Scientists Have Identified 5 Distinct Subtypes ETV Bharat
Reading Insights
Total Reads
1
Unique Readers
7
Time Saved
56 min
vs 56 min read
Condensed
99%
11,194 → 67 words
Want the full story? Read the original article
Read on Nature